Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : The collaboration will support Sanofi’s use of CytoReason’s computational disease models to develop new targets for inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
January 23, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Pfizer Inc
Deal Size : $110.0 million
Deal Type : Expanded Collaboration
Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development
Details : The new research agreement and investment will support the development of additional disease models and the creation of high-resolution models, spanning across a number of therapeutic areas.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : $20.0 million
September 20, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Pfizer Inc
Deal Size : $110.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : The new research agreement and investment will support the development of additional disease models and the creation of high-resolution models, spanning across a number of therapeutic areas.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
September 20, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
CytoReason Collaborates with Merck KGaA, Darmstadt, Germany, on Cancer Immunotherapy Drug
Details : This collaboration might help identify which type of tumor the drug will be most effective for, and has the potential to save the lives of millions who suffer from cancer.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
October 20, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?